Advertisement
Advertisement
AMGN
Amgen Inc
346.25
USDSponsored
+8.23
+2.43%
Apr 30, 16:00 UTC -4
Closed
Pre-Market
339.50
-6.75
-1.95%
AMGN Earnings Reports
Positive Surprise Ratio
AMGN beat 37 of 41 last estimates.
90%
Next Report
Date of Next Report
Aug 03, 2026
Estimate for Q2 26 (Revenue/ EPS)
$9.63B
/$5.85
Implied change from Q1 26 (Revenue/ EPS)
+11.79%
/+13.59%
Implied change from Q2 25 (Revenue/ EPS)
+4.96%
/-2.82%
Amgen Inc earnings per share and revenue
On Apr 30, 2026, AMGN reported earnings of 5.15 USD per share (EPS) for Q1 26, beating the estimate of 4.85 USD, resulting in a 6.15% surprise. Revenue reached 8.62 billion, compared to an expected 8.75 billion, with a -1.52% difference.
Looking ahead to Q2 26, 13 analysts forecast an EPS of 5.85 USD, with revenue projected to reach 9.63 billion USD, implying an increase of 13.59% EPS, and increase of 11.79% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Bristol-Myers Squibb Co.
Report Date
Apr 30, 2026 For Q1 26
Estimate
$1.42
Actual
$1.58
Surprise
+10.95%
Alnylam Pharmaceuticals, Inc.
Report Date
Apr 30, 2026 For Q1 26
Estimate
$0.95
Actual
$1.99
Surprise
+108.95%
Moderna, Inc. Common Stock
Report Date
May 01, 2026 For Q1 26
Estimate
-$3.32
Actual
-$1.18
Surprise
+64.48%
Illumina Inc
Report Date
Apr 30, 2026 For Q1 26
Estimate
$1.07
Actual
$1.14
Surprise
+6.94%
Bio-Rad Laboratories, Inc. Class B
Report Date
Apr 30, 2026 For Q1 26
Estimate
$2.00
Actual
$1.89
Surprise
-5.68%
Kymera Therapeutics, Inc. Common Stock
Report Date
Apr 30, 2026 For Q1 26
Estimate
-$0.89
Actual
-$0.71
Surprise
+21.05%
Syndax Pharmaceuticals, Inc.
Report Date
Apr 30, 2026 For Q1 26
Estimate
-$0.59
Actual
-$0.48
Surprise
+19.15%
NovoCure Limited Ordinary Shares
Report Date
Apr 30, 2026 For Q1 26
Estimate
-$0.52
Actual
-$0.62
Surprise
-18.52%
Phathom Pharmaceuticals, Inc. Common Stock
Report Date
Apr 30, 2026 For Q1 26
Estimate
-$0.32
Actual
-$0.18
Surprise
+45.22%
Pacira BioSciences, Inc. Common Stock
Report Date
Apr 30, 2026 For Q1 26
Estimate
$0.57
Actual
$0.60
Surprise
+4.42%
FAQ
What were Amgen Inc's earnings and revenue for the latest quarter Q1 2026?
For Q1 2026, Amgen Inc reported EPS of $5.15, beating estimates by 6.15%, and revenue of $8.62B, -1.52% below expectations.
How did the market react to Amgen Inc's Q1 2026 earnings?
The stock price moved -- --, changed from -- before the earnings release to -- the day after.
When is Amgen Inc expected to report next?
The next earning report is scheduled for Aug 03, 2026.
What are the forecasts for Amgen Inc's next earnings report?
Based on 13
analysts, Amgen Inc is expected to report EPS of $5.85 and revenue of $9.63B for Q2 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement